Lead Sponsor

Novartis Pharmaceuticals

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

•Naive primary hypertension patients or primary hypertensive patients on mono antihypertensive therapy:
•All treatment-naive patients need to have 140mmHg≤MSSBP\<180mmHg and 90mmHg≤MSDBP\< 110mmHg at visit 1
•For patients on mono antihypertensive therapy, MSSBP/MSDBP should \<160/100mmHg at visit 1 (the beginning of screening period); and at visit 2(the beginning of theraputic period), they should have MSSBP≥140 mmHg and \<180mmHg AND MSDBP≥90 mmHg and \<110mmHg

•Severe hypertension
•Malignant hypertension
•Secondary hypertension
•Renal dysfunction(serum creatinine \> 2.0mg(176.8μmol/L)at visit 1)
•Hepatic disease
•History of hypertensive encephalopathy or cerebrovascular accident within 6 months
•History of myocardial infarction, coronary revascularization within 6 months
•Type 1 diabetes mellitus
•patietns with HbA1c \>8% at visit 1
•Women in pregnancy and lactation
•Potentially fertile female patients not using effective contraceptive methods
•Be allergy to study drug.
•Other protocol defined inclusion/exlusion criteria may apply